GLABF (Gemina Laboratories) Days Sales Outstanding: 0.00 (As of Oct. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Gemina Laboratories Days Sales Outstanding?

Gemina Laboratories GLABF -27.59% Days Sales Outstanding is 0.00 as of Oct. 2025. The stock has 2 warning signs investors should review.

Gemina Laboratories's average Accounts Receivable for the three months ended in Oct. 2025 was $0.00 Mil. Gemina Laboratories's Revenue for the three months ended in Oct. 2025 was $0.00 Mil.

The historical rank and industry rank for Gemina Laboratories's Days Sales Outstanding or its related term are showing as below:

GLABF's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 68.94
* Ranked among companies with meaningful Days Sales Outstanding only.

Gemina Laboratories's Days Sales Outstanding stayed the same from Oct. 2024 (0.00) to Oct. 2025 (0.00).

Gemina Laboratories  (OTCPK:GLABF) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Gemina Laboratories Days Sales Outstanding Related Terms

Gemina Laboratories Days Sales Outstanding Historical Data

* Premium members only.

The historical data trend for Gemina Laboratories's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gemina Laboratories Days Sales Outstanding Chart

Gemina Laboratories Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
Days Sales Outstanding
0.00 0.00 0.00 0.00 0.00

Gemina Laboratories Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GLABF vs VRTX, REGN, ALNY: Days Sales Outstanding Comparison

For the Biotechnology subindustry, Gemina Laboratories's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gemina Laboratories Days Sales Outstanding vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gemina Laboratories's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Gemina Laboratories's Days Sales Outstanding falls into.


Gemina Laboratories Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Gemina Laboratories's Days Sales Outstanding for the fiscal year that ended in Jan. 2025 is calculated as

Days Sales Outstanding (A: Jan. 2025 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jan. 2024 ) + Accounts Receivable (A: Jan. 2025 )) / count ) / Revenue (A: Jan. 2025 )*Days in Period
=( (0 + 0) / 1 ) / 0*365
=0 / 0*365
=N/A

Gemina Laboratories's Days Sales Outstanding for the quarter that ended in Oct. 2025 is calculated as:

Days Sales Outstanding (Q: Oct. 2025 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jul. 2025 ) + Accounts Receivable (A: Oct. 2025 )) / count ) / Revenue (A: Oct. 2025 )*Days in Period
=( (0 + 0) / 1 ) / 0*365 / 4
=0 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Sales Outstanding →
What does a Days Sales Outstanding of 0.00 mean?
Gemina Laboratories (GLABF) has a Days Sales Outstanding of 0.00 as of Oct. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Gemina Laboratories and its competitors.
Is Gemina Laboratories' Days Sales Outstanding too high?
Gemina Laboratories' current Days Sales Outstanding is 0.00.
How does Gemina Laboratories' Days Sales Outstanding compare to VRTX and REGN?
Gemina Laboratories' Days Sales Outstanding of 0.00 can be compared against companies in the Biotechnology industry. The industry median Days Sales Outstanding is 68.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Gemina Laboratories and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gemina Laboratories's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gemina Laboratories stock overvalued right now?
Gemina Laboratories (GLABF) has a current Days Sales Outstanding of 0.00. The current Days Sales Outstanding is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Gemina Laboratories (GLABF), the current Days Sales Outstanding is 0.00 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gemina Laboratories Business Description

Address 3600 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8
Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.